Patents by Inventor Timothy London

Timothy London has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains
    Patent number: 11890302
    Abstract: The present invention relates to gamma delta (??) T cells and/or Natural Killer (NK) cells expressing constructs to provide for the expression of a Chimeric Antigen Receptor (CAR) incorporating the signalling domain of FCY Receptors. Suitably the invention also relates to constructs to provide such CARs and methods for introducing such CARs into cells and expressing such CARs in cells comprising receptors of gamma delta (??) T cells and/or Natural Killer (NK) cells.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: February 6, 2024
    Assignee: TC BIOPHARM LIMITED
    Inventors: Agapitos Patakas, Timothy London, Emilio Cosimo
  • Methods Of Cell Selection
    Publication number: 20210356377
    Abstract: The present invention is directed to methods of screening populations of transgenic cells for cells that produce a protein of interest. The methods comprise culturing transgenic cells in culture conditions that include at least one non-natural amino acid (nnAA) in the cell culture medium. The transgenic cells comprise at least one polynucleotide that codes for a fusion protein with a first domain coding for a protein of interest and a second domain coding for a domain that facilitates detection of the transgenic cells that express the protein of interest when the transgenic cell expresses the second domain.
    Type: Application
    Filed: September 5, 2019
    Publication date: November 18, 2021
    Inventors: Zachary BRITTON, Marcello MARELLI, Michael A. BOWEN, Timothy LONDON, Li ZHUANG, Lina CHAKRABARTI
  • IMMUNE CELLS WITH MODIFIED METABOLISM AND THEIR USE THEREOF
    Publication number: 20200384020
    Abstract: A modified T cell is described which is adapted to overexpress SLC1A5, an isoform of SLC1A5 or an alternative tryptophan or glutamine transporter. Further described is the use of such modified T cells in the treatment of disease, in particular cancer, methods to select modified T cells which overexpress SLC1A5 and nucleic acids and vectors to provide for such modified T cells.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 10, 2020
    Inventors: TIMOTHY LONDON, AGAPITOS PATAKAS, ADELE HANNIGAN, EMILIO COSIMO, NANCY COYLE, ANGELA SCOTT, MICHAEL LEEK
  • Modified CAR-T
    Publication number: 20200289564
    Abstract: The present invention relates to gamma delta (??) T cells and/or Natural Killer (NK) cells expressing constructs to provide for the expression of a Chimeric Antigen Receptor (CAR) incorporating the signalling domain of FCY Receptors. Suitably the invention also relates to constructs to provide such CARs and methods for introducing such CARs into cells and expressing such CARs in cells comprising receptors of gamma delta (??) T cells and/or Natural Killer (NK) cells.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 17, 2020
    Inventors: Agapitos Patakas, Timothy London, Emilio Cosimo